By targeting the MUC1 glycoprotein that is overexpressed in breast, lung, ovarian, and pancreatic cancer, our nanoconjugate shows immense promise for efficient cancer therapy. This evidence concerns the gene MUC1 and familial pancreatic carcinoma.